Behavioural Neurology最新文献

{"title":"Nonlinear Association of Daily Sitting Time With Depression Risk in US Adults: A Cross-Sectional Study.","authors":"Zhimao Cai, Hualang Cai, Rui Jia, Hui Peng, Youlian Luo, Jiashuang Lin, Ye Ye, Sixia Chen, Yueqian Wang, Rourou Li, Mengjia Chen, Weifeng Chen","doi":"10.1155/bn/7167267","DOIUrl":"https://doi.org/10.1155/bn/7167267","url":null,"abstract":"<p><strong>Background: </strong>Previous studies have examined the relationship between daily sitting time and depression, yet the specific dose-response relationship remains unclear.</p><p><strong>Methods: </strong>This study analyzed data from 29,691 participants in the 2007-2018 National Health and Nutrition Examination Survey (NHANES). To delve into the possible nonlinear link between daily sitting time and depression, smooth curve fitting and threshold effect analysis were utilized in the study. Information on daily sitting time was collected through questionnaires, and the Patient Health Questionnaire-9 (PHQ-9) was employed to measure depression.</p><p><strong>Results: </strong>In the fully adjusted Model 3, each additional hour of sitting was associated with a 5% increase in the risk of depression (95% CI: 1.02, 1.07, p = 0.0002). When categorizing daily sitting time, participants who sat for 8 h or more daily exhibited a significantly higher risk of depression across all models. In Model 3, this group had an odds ratio (OR) of 1.37 (95% CI: 1.12, 1.69, p = 0.0039) compared with the reference group sitting for less than 4 h. The threshold effect analysis identified 7 h as the inflection point. Below this threshold, no significant correlation was observed. In contrast, when daily sitting time exceeded the threshold, there was a significant increase in the risk of depression, with an OR of 1.07 (95% CI: 1.01, 1.12, p = 0.0184).</p><p><strong>Conclusions: </strong>A nonlinear association exists between daily sitting time and depression risk in US adults. However, additional research is required to further validate this finding.</p>","PeriodicalId":50733,"journal":{"name":"Behavioural Neurology","volume":"2026 1","pages":"e7167267"},"PeriodicalIF":2.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147437150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Executive Function in Patients With Temporal Lobe Epilepsy Through a Game-Based Assessment Task.","authors":"Guang Yao, Shirui Wen, Quanji Li, Yin Liu, Beibing Li, Zhi Song, Li Feng, Ding Liu","doi":"10.1155/bn/6284292","DOIUrl":"https://doi.org/10.1155/bn/6284292","url":null,"abstract":"<p><strong>Objectives: </strong>Temporal lobe epilepsy (TLE) is often accompanied by executive function (EF) impairment, highlighting the need for accessible and quantitative assessment approaches. In this study, we applied our previously developed game-based executive function assessment tool (EFAT) to evaluate EF performance in TLE patients.</p><p><strong>Methods: </strong>Thirty-two TLE patients and 29 healthy controls (HCs) completed a comprehensive battery of standardized tests, including the Stroop Color-Word Test (SCWT) and the Trail Making Test (TMT), as well as the EFAT. Metrics from the EFAT (number of touches, number of correct guesses, accuracy, and learning latency) were selected and analyzed.</p><p><strong>Results: </strong>Compared with HCs, TLE patients showed significant EF deficits, including longer completion times on TMT-A (t(59) = 4.42, p < 0.001) and TMT-B (t(59) = 3.50, p = 0.001), as well as poorer SCWT-1 performance (t(59) = 2.22, p = 0.036). In the EFAT, TLE patients exhibited more touches (t(59) = -2.75, p = 0.008), fewer correct guesses (t(59) = -3.74, p < 0.001), and lower accuracy (t(59) = -2.65, p = 0.010). Game-derived metrics were significantly correlated with TMT scores.</p><p><strong>Conclusions: </strong>EFAT detected executive deficits in TLE patients across social and nonsocial conditions and offered an objective, engaging complementary tool for EF assessment. These findings support its preliminary clinical applicability.</p>","PeriodicalId":50733,"journal":{"name":"Behavioural Neurology","volume":"2026 1","pages":"e6284292"},"PeriodicalIF":2.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147678612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Experience of Sustained-Release Fampridine in Chinese Patients With Multiple Sclerosis: A Case Series on Walking Impairment and Fatigue.","authors":"Han Wang, Wenting Zhang, Fengjun Wang, Qin Wang, Tao Yang, Runze Zhao, RongRong Wang, Antonio Carrillo-Vico, Guillermo Izquierdo, Yu Zhang, Xiongfei Zhao, Guoxun Zhang","doi":"10.1155/bn/6426255","DOIUrl":"10.1155/bn/6426255","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the efficacy of sustained-release fampridine tablets (fampridine-SR) on walking impairment and fatigue on Chinese patients with multiple sclerosis (MS).</p><p><strong>Methods: </strong>All patients (<i>n</i> = 12) had the baseline Expanded Disability Status Scale (EDSS) at 4-7 and orally administered fampridine-SR at 10 mg twice per day for at least 12 weeks. All patients were assessed using EDSS, Timed 25-Foot Walk (T25FW), the 12-item Multiple Sclerosis Walking Scale (MSWS-12), and Modified Fatigue Impact Scale (MFIS) at baseline, day 1, week 1, 2, 4, 8, and 12.</p><p><strong>Results: </strong>The baseline EDSS score was 4.67 ± 0.36. Fampridine-SR significantly decreased the EDSS score by 0.63 ± 0.20 (<i>p</i> = 0.011) after 12-week treatment. T25FW was changed at day 1 and week 1 by - 12.73 ± 3.03% and - 14.20 ± 4.36% (<i>p</i> < 0.011), respectively. The statistically and clinically significant improvement of MSWS-12 was observed since week 1. The total, cognitive subscale, physical subscale, and psychosocial subscale of MFIS were significantly reduced in Chinese patients with MS.</p><p><strong>Conclusion: </strong>Fampridine-SR was a fast-acting oral potassium channel blocker on improving walking ability of MS as early as day 1. It demonstrated the positive effects on walking impairment and fatigue, including the physical, cognitive, and psychosocial subscales of MFIS, in Chinese patients with MS.</p>","PeriodicalId":50733,"journal":{"name":"Behavioural Neurology","volume":"2025 ","pages":"6426255"},"PeriodicalIF":2.3,"publicationDate":"2025-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12740591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145851420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brivaracetam Combined With Topiramate at Low Doses Alleviates Neurobehavioral Deficits and Oxidative Stress in a Chemoconvulsant Kindled Seizure Model.","authors":"Khaled Ahmed Saghir, Waseem Ashraf, Rana Muhammad Zahid Mushtaq, Faleh Alqahtani, Imran Imran","doi":"10.1155/bn/8037864","DOIUrl":"10.1155/bn/8037864","url":null,"abstract":"<p><p>Epilepsy is a long-lasting neurological condition often associated with cognitive and behavioral comorbidities, such as anxiety, depression, and memory deficits. This study examined the therapeutic effect of topiramate (TPM) and brivaracetam (BRV), both separately and combined, using pentylenetetrazole-kindled mice. Seizure severity was visually observed during the kindling process. After that, mice underwent a series of behavioral tests to evaluate anxiety, depression, and memory performance. Subsequently, neurochemical analyses were performed to assess cholinergic activity and oxidative stress markers. The TPM + BRV group showed significantly attenuated seizure progression during all PTZ doses (<i>p</i> < 0.001), with an 88.4% reduction in seizure scores compared to monotherapies. PTZ-kindled mice showed marked behavioral impairments and biochemical imbalances, including elevated oxidative stress and acetylcholinesterase activity. While monotherapy with BRV or TPM displayed partial improvements, combined therapy provided significantly greater effects, enhancing central explorations (152% and 259.6%), sociability (195.2%), memory retention (508.4% for discrimination index and 463.9% for aversive awareness), and reducing depressive-like behaviors (52.7%-73.7%). Biochemically, the combined treatment restored antioxidant enzyme levels (SOD, CAT, and GPx) by 45%-70% and significantly lowered MDA levels (70.7%) and restored SOD activity (220.9%). These findings suggest that low-dose rational polytherapy with TPM and BRV may enhance seizure control and ameliorate associated neuropsychiatric and oxidative imbalance.</p>","PeriodicalId":50733,"journal":{"name":"Behavioural Neurology","volume":"2025 ","pages":"8037864"},"PeriodicalIF":2.3,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12698180/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145758238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alzheimer's Disease: The Current and Emerging Treatment Approaches.","authors":"Runxuan Pang, Qi Jia, Chen Ma, Tinghai Li, Wenliang Bi, Hongyang Wang, Rongyu Liu, Pengyuan Chen, Eui-Seok Lee, Heng Bo Jiang","doi":"10.1155/bn/9627699","DOIUrl":"10.1155/bn/9627699","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a chronic progressive neurodegenerative disease characterized by amyloid <i>β</i> (A<i>β</i>) plaques and neurofibrillary tangles (NFTs) as its main pathological features. It mainly manifests as cognitive dysfunction, and its pathological process may occur before symptom onset. However, the current drugs and methods for treating AD have unsatisfactory therapeutic outcomes. Therefore, finding a treatment that can inhibit the progression of AD by targeting its pathological features is an urgent need. This review summarizes the current traditional drugs that can delay the progression of AD and new drugs that act on the pathological characteristics of AD and highlights the potential value of related plant extracts. In addition, this review explores the application of different vectors, such as viral vectors and nanoparticles, in gene therapy and drug delivery. These data will provide novel ideas for new drug development and the search for new therapeutic mechanisms.</p>","PeriodicalId":50733,"journal":{"name":"Behavioural Neurology","volume":"2025 ","pages":"9627699"},"PeriodicalIF":2.3,"publicationDate":"2025-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12682927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145716551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4-Methylumbelliferone (4-MU) Improves Learning and Memory After Cerebral Ischemia/Reperfusion Injury in Rats.","authors":"Shaghayegh Tamouk, Hamzeh Mirshekari Jahangiri, Elham Kashafi Jahromi, Michael R Hamblin, Nahid Aboutaleb, Fatemeh Ramezani","doi":"10.1155/bn/5900565","DOIUrl":"10.1155/bn/5900565","url":null,"abstract":"<p><strong>Background: </strong>Stroke is the sixth leading cause of death and lifelong disability for millions of people in the United States. Cerebral ischemia leads to oxidative stress, excitotoxicity, inflammation, and apoptosis; additionally, impairment in memory and learning occurs in the majority of subjects with ischemic stroke. The lack of definitive treatment has sparked extensive research into novel therapeutic strategies, including the use of 4-methylumbelliferone (4-MU), a coumarin derivative with potential neuroprotective properties. The present study examines the impact of 4-MU on reducing cerebral ischemia-reperfusion (I/R) injury and learning and memory impairments in male Wistar rats.</p><p><strong>Methods: </strong>Animals were exposed to middle cerebral artery occlusion (MCAO) and treated with a single dose of 4-MU (25 mg/kg) dissolved in 0.9% DMSO. An automated shuttle box and Morris water maze (MWM) tests were employed to evaluate learning and memory impairments. Western blot assay, TTC staining, and Nissl staining were used to measure protein expression, infarct volume, and cell death, respectively.</p><p><strong>Results: </strong>Treatment with 4-MU reduced infarct volume and improved learning and memory impairments by downregulating HAS1 and HAS2. 4-MU modulated the release of proinflammatory cytokines including TNF-<i>α</i> and IL-1<i>β</i>, as well as anti-inflammatory markers like IL-10, and reduced oxidative stress markers in the brain.</p><p><strong>Conclusion: </strong>The neuroprotective effects of 4-MU against cerebral I/R injury can be attributed to the downregulation of HAS1 and HAS2.</p>","PeriodicalId":50733,"journal":{"name":"Behavioural Neurology","volume":"2025 ","pages":"5900565"},"PeriodicalIF":2.3,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12680788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145702934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondhand Smoke Exposure and Depressive Symptoms Among Nonsmokers in China.","authors":"Xia Cui, Wei Sen Zhang, Lin Xu","doi":"10.1155/bn/1170641","DOIUrl":"10.1155/bn/1170641","url":null,"abstract":"<p><strong>Background: </strong>Secondhand smoke exposure (SHSE) remains widespread in China and may be linked to mental health outcomes, yet evidence among older adults is limited. We examined the association between SHSE and depressive symptoms in a large cohort of nonsmoking older Chinese adults.</p><p><strong>Methods: </strong>We conducted a cross-sectional analysis of 7958 nonsmoking participants aged 50 years or older from the Guangzhou Biobank Cohort Study. SHSE was assessed through structured interviews and quantified as cumulative exposure (in years at 40 h/week) and by context (home and workplace). Depressive symptoms were measured using the 15-item Geriatric Depression Scale (GDS-15). Linear regression models were used to examine associations between SHSE and GDS-15 scores, adjusting for age, sex, education, occupation, income, physical activity, and alcohol use.</p><p><strong>Results: </strong>Higher cumulative SHSE was associated with greater depressive symptom severity. Participants with more than 5 years of exposure had significantly higher GDS-15 scores than those with less than 2 years (adjusted <i>β</i> 0.21, 95% CI 0.09-0.32; <i>p</i> < 0.001). Workplace exposure was independently associated with higher GDS-15 scores (<i>β</i> 0.23, 95% CI 0.08-0.38), while the association for home exposure was weaker and nonsignificant after adjustment. A greater number of smokers and higher frequency of SHSE at home were also linked to elevated GDS-15 scores. No associations were observed with childhood exposure.</p><p><strong>Conclusion: </strong>Among older nonsmoking adults, prolonged SHSE, particularly in workplace settings, showed a positive association with depressive symptom severity, although the direction of this association cannot be determined. These cross-sectional associations warrant investigation in prospective studies to determine whether SHSE exposure precedes depression onset and whether the relationship is causal or reflects shared risk factors.</p>","PeriodicalId":50733,"journal":{"name":"Behavioural Neurology","volume":"2025 ","pages":"1170641"},"PeriodicalIF":2.3,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12628081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145566168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers in Schizophrenia: Current Approaches and New Developments-A Literature Review.","authors":"Alicja Sierakowska, Ewa Niewiadomska, Sebastian Łabuda, Anna Bieniasiewicz, Mateusz Roszak, Beata Łabuz-Roszak","doi":"10.1155/bn/2991323","DOIUrl":"10.1155/bn/2991323","url":null,"abstract":"<p><p>Schizophrenia (SZ) is categorized as a chronic severe highly heritable brain disease. Symptoms include positive, negative, and cognitive symptoms. Despite numerous theories concerning the etiopathogenesis of SZ, the symptoms, although characteristic in their phenomenology, manifest themselves in a rather heterogeneous manner, which makes them subject to clinical assessment and, at the same time, prone to errors resulting from diverse interpretations of the context of the patient's statements. Therefore, current research is focusing on identifying more subtle and stable features of SZ, such as the phenotype, endophenotype, and assessable abnormalities devoid of human clinical observation. The various biomarker developments focus on the role of transmitters and their corresponding receptors, in particular: glutamate, acetylcholine, dopamine, or serotonin. Also important in terms of etiopathogenesis remain growth factors such as brain-derived neurotrophic factor (BDNF), nerve growth factor receptor (NGFR), or vascular endothelial growth factor (VEGF). More recently, research has emphasized the role of inflammatory processes and secreted pro- as well as anti-inflammatory cytokines, included in the class of interleukins, chemokines, and tumor necrosis factors, as well as on inflammatory markers-C-reactive protein (CRP) or glutathione (GSH). Increasingly, changes at the genetic level have been implicated as the cause of diseases, and it is now believed that noncoding RNAs (micro-RNA [miRNA], long noncoding RNA [lnc-RNA], and circular RNA [circRNA]) are involved in the development of SZ. Among the genes that may prove to be potential biomarkers in SZ belong SEDT1A, FOXP2, GRIN2A, GRIA3, NRN1, BDNF, CACNA1C, and ZNF8A4. The peptide group molecules, Phospholipase A2, Klotho protein, and soluble urokinase plasminogen activator receptor (suPAR), also remain consistently important. From the perspective of SZ as a disease associated with neuronal damage, biomarkers correlating with brain injury, neuron-specific enolase (NSE), and S100B protein should be considered.</p>","PeriodicalId":50733,"journal":{"name":"Behavioural Neurology","volume":"2025 ","pages":"2991323"},"PeriodicalIF":2.3,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12539668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145373370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intelligent Assessment Techniques for Abnormal Movement Patterns in Neurological Disorders: Applications and Advances.","authors":"Yunjun Bao, Ronghua Hong, Wenting Qin, Zhuang Wu, Yunping Song, Lingjing Jin","doi":"10.1155/bn/6006064","DOIUrl":"10.1155/bn/6006064","url":null,"abstract":"<p><p>Neurological disorders frequently result in diverse forms of abnormal movement. Conventional clinical assessment approaches often lack the precision and objectivity needed to evaluate muscle involvement and associated functional limitations. With the development of various intelligent assessment devices, technologies such as wearable sensors, motion capture, radar, and imaging technology, which are based on myoelectricity, kinematics, mechanics, and optics, combined with mathematical models and algorithms, have been widely used for abnormal movement recognition. These technologies further improve the accuracy and validity of clinical evaluation. In this paper, we review the latest advances in intelligent technologies that help clinicians qualitatively and quantitatively assess abnormal movement patterns and carry out personalized rehabilitation treatment. Our work was also aimed at summarizing the research and application of intelligent assessment techniques.</p>","PeriodicalId":50733,"journal":{"name":"Behavioural Neurology","volume":"2025 ","pages":"6006064"},"PeriodicalIF":2.3,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12515573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145294374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Burnout and Life Satisfaction among Healthcare Workers Related to the COVID-19 Pandemic (Silesia, Poland)\".","authors":"","doi":"10.1155/bn/9869136","DOIUrl":"https://doi.org/10.1155/bn/9869136","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1155/2024/9945392.].</p>","PeriodicalId":50733,"journal":{"name":"Behavioural Neurology","volume":"2025 ","pages":"9869136"},"PeriodicalIF":2.3,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12500348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145245761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}